Emerging Infectious Disease ISSN: 1080-6059

Ebola Virus Antibody Prevalence in Dogs and Human Risk

Loïs Allela*, Olivier Bourry*, Régis Pouillot†, André Délicat*, Philippe Yaba*, Brice Kumulungui*, Pierre Rouquet*, Jean-Paul Gonzalez‡, and Eric M. Leroy*‡

Author affiliations: *Centre International de Recherches Médicales de Franceville, Franceville, Gabon; †Centre Pasteur du Cameroun, Yaoundé, Cameroun; ‡Institut de Recherche pour le Développement, Paris, France

Main Article

Figure 2

Seroprevalence of Ebola virus in dogs sampled in different areas: A) France, major towns of Gabon, Mekambo (a town close to the disease-epidemic area) and villages in the epidemic area; B) France, major towns of Gabon, Mekambo, villages without human cases and villages with human cases; C) France, major towns of Gabon, Mekambo, villages with and without an animal source. Estimates are represented by squares, bounded by their 95% Clopper and Pearson confidence intervals. The dashed line is the li

Figure 2. . . Seroprevalence of Ebola virus in dogs sampled in different areas: A) France, major towns of Gabon, Mekambo (a town close to the disease-epidemic area) and villages in the epidemic area; B) France, major towns of Gabon, Mekambo, villages without human cases and villages with human cases; C) France, major towns of Gabon, Mekambo, villages with and without an animal source. Estimates are represented by squares, bounded by their 95% Clopper and Pearson confidence intervals. The dashed line is the linear trend in proportion.

Main Article

^¹Loïs Allela and Olivier Bourry contributed equally to this work.

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.